Visual impairment as a function of visual acuity in both eyes and its impact on patient reported preferences

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Finger, Robert P ^a,b   Fenwick, Eva ^a   Hirneiss, Christoph W ^d   Hsueh, Arthur ^a   Guymer, Robyn H ^a   Lamoureux, Ecosse L ^a,c   Keeffe, Jill E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BONN   (Germany)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EQ 5D; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; QUALITY OF LIFE INDEX; SCORING SYSTEM; VISION AND QUALITY OF LIFE INDEX; VISUAL ACUITY; VISUAL IMPAIRMENT; MIDDLE AGED; PATHOPHYSIOLOGY; QUALITY OF LIFE; SELF REPORT; VISUAL DISORDER;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SELF REPORT; VISION DISORDERS; VISUAL ACUITY;

EID: 84891925742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081042     Document Type: Article

References (26)

1. Hurley SF, Matthews JP, Guymer RH (2008) Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 6:12.
2. Mitchell P, Annemans L, White R, Gallagher M, Thomas S (2011) Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 29:107-131.
3. Bourne R, Price H, Stevens G (2012) Global burden of visual impairment and blindness. Archives of ophthalmology 130:645-647.
4. Sharma S, Brown GC, Brown MM, Shah GK, Snow K, et al. (2000) Converting visual acuity to utilities. Canadian journal of ophthalmology Journal canadien d'ophtalmologie 35:267-272.
5. Vu HT, Keeffe JE, McCarty CA, Taylor HR (2005) Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol 89:360-363. (Pubitemid 40327623)
6. Finger RP, Hoffmann AE, Fenwick EK, Wolf A, Kampik A, et al. (2012) Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine. The British journal of ophthalmology 96:997-1002.
7. National Institute for Health and Clinical Excellence (NICE) (2007) NICE issues draft guidance on drugs for the treatment of age related macular degeneration. National Institute for Health and Clinical Excellence (NICE).
8. Finger R, Hoffmann AE, Fenwick EK, Wolf A, Kampik A, et al. (2012) Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine. The British journal of ophthalmology.
9. Williams A (1990) EuroQol - a new facility for the measurement of healthrelated quality of life. Health Policy 16:199-208.
10. Brown GC (1999) Vision and quality-of-life. Trans Am Ophthalmol Soc 97:473-511. (Pubitemid 30106064)
11. Brown MM, Brown GC, Sharma S, Garrett S (1999) Evidence-based medicine, utilities, and quality of life. Curr Opin Ophthalmol 10:221-226. (Pubitemid 29263948)
12. Brown MM, Brown GC, Sharma S, Busbee B, Brown H (2001) Quality of life associated with unilateral and bilateral good vision. Ophthalmology 108:643-647; discussion 647-648. (Pubitemid 32238453)
13. Brown GC, Brown MM, Sharma S, Beauchamp G, Hollands H (2001) The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 99:199-203; discussion 203-194.
14. Hirneiss C, Rombold F, Kampik A, Neubauer AS (2006) [Visual quality of life after vitreoretinal surgery for epiretinal membranes]. Ophthalmologe 103:109-113.
15. Peacock S, Misajon R, Iezzi A, Richardson J, Hawthorne G, et al. (2008) Vision and quality of life: development of methods for the VisQoL vision-related utility instrument. Ophthalmic Epidemiol 15:218-223.
16. Hiratsuka Y, Yamada M, Murakami A, Okada AA, Yamashita H, et al. (2011) Cost-effectiveness of cataract surgery in Japan. Jpn J Ophthalmol 55:333-342.
17. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095-1108. (Pubitemid 127453463)
18. Devlin N, Hansen P, Kind P, Williams A (2003) Logical inconsistencies in survey respondents' health state valuations - a methodological challenge for estimating social tariffs. Health Economics 12:529-544. (Pubitemid 36818030)
19. Misajon R, Hawthorne G, Richardson J, Barton J, Peacock S, et al. (2005) Vision and quality of life: the development of a utility measure. Investigative ophthalmology & visual science 46:4007-4015. (Pubitemid 44264599)
20. Fenwick EK, Xie J, Ratcliffe J, Pesudovs K, Finger RP, et al. (2012) The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Investigative ophthalmology & visual science 53:677-684.
21. Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, et al. (2010) Visionrelated function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 117:747-756 e744.
22. Hirneiss C, Neubauer AS, Gass CA, Reiniger IW, Priglinger SG, et al. (2007) Visual quality of life after macular hole surgery: outcome and predictive factors. The British journal of ophthalmology 91:481-484. (Pubitemid 46623681)
23. Bansback N, Czoski-Murray C, Carlton J, Lewis G, Hughes L, et al. (2007) Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res 16:533-543. (Pubitemid 46363686)
24. Bansback N, Davis S, Brazier J (2007) Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic agerelated macular degeneration. Eye (Lond) 21:1455-1463.
25. Holton H, Christiansen AB, Albeck MJ, Johnsen CR (2009) The impact of light source on discrimination ability in subjects with age-related macular degeneration. Acta Ophthalmol.
26. Espallargues M, Czoski-Murray CJ, Bansback NJ, Carlton J, Lewis GM, et al. (2005) The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 46:4016-4023. (Pubitemid 44264600)